VetrixBio is now Vetarys. The new corporate name reflects the company's continued evolution and long-term vision for advancing therapies for companion animals. The name Vetarys is inspired by two roots…
Read More
© 2026 Vetarys
Today at the 6th International Veterinary Pain Short Course hosted at NC State College of Veterinary Medicine, Vetarys presented the first clinical data for VTX-304, its investigational bispecific antibody designed…
Read More
Vetarys today highlighted the strength of its leadership and advisory team, bringing together experience across biotechnology, veterinary medicine, and drug development. The company is supported by a group of advisors with…
Read More
Vetarys today announced preliminary safety and efficacy data from its first in vivo study of VTX-304, the company’s lead program for osteoarthritis in dogs. The study, conducted in a natural…
Read More
Vetarys today provided an update on its oncology program, highlighting continued progress in the development of VTX-301/302, a localized immunotherapy combination for the treatment of cancer in companion animals. The program…
Read More
Vetarys today highlighted its development strategy in osteoarthritis, centered on a dual-target biologic approach designed to address both pain and the underlying progression of disease. Osteoarthritis is one of the…
Read More
Graham Lumsden and Peter Hanson today announced the formation of Vetarys, a biotechnology company focused on developing novel therapies for companion animals. Vetarys was founded on a simple premise: pets…
Read More